a Twitter thread from @ANI

1.

DCGI has granted permission for emergency use of therapeutic application of drug 2-deoxy-D-glucose (2-DG) as adjunct therapy in moderate to severe COVID-19 patients. Being a generic molecule & analogue of glucose, it can be easily produced & made available in plenty: DRDO

2.

The drug has been developed by DRDO lab Institute of Nuclear Medicine & Allied Sciences in collaboration with Dr Reddy’s Laboratories. Clinical trial have shown that this molecule helps in faster recovery of hospitalized patients & reduces supplemental oxygen dependence: DRDO

3.

Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. In efficacy trends, the patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints: DRDO

4.

The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production: DRDO

Read this thread on Twitter